Skip to main content
EVH logo

EVH · Evolent Health, Inc.

Track EVH — free
$3.90 +0.47 (+13.70%) At close · Nov 20
Market Cap
$441.11M
Shares
113.11M
Volume · Nov 20 4.42M Avg daily vol (3M) 2.16M

Price & Indicators

 

Key stats

Close
$3.90
Fri 20 Nov
Open
$3.44
Fri 20 Nov
Average volume, 30 days
2.0M
shares a session
Short interest
10.6M
9.4% of shares · 7.0 days to cover
Day range
$3.44$4.16
Open $3.44 Close $3.90
52-week closing range
$2.17$6.19
Close $3.90 37.0% under the high
Short volume, last session
68%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Feb 23, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 5
Earnings call
Adjusted EBITDA guidance raised to $130 million to $135 million

Evolent reported $725 million of quarterly revenue and $34.3 million of adjusted EBITDA, up approximately 22% sequentially, while raising full-year adjusted EBITDA guidance to $130 million to $135 million and reiterating revenue guidance of $2.6 billion to $2.7 billion.

2 source passages
Total revenue was $725 million, up approximately 11% versus the second quarter. Adjusted EBITDA was $34.3 million, up approximately 22% sequentially. We are reiterating revenue guidance of $2.6 billion to $2.7 billion and raising our adjusted EBITDA guidance to $130 million to $135 million from $120 million to $135 million previously. Open the document at this passage
Nov 5
Current report 8-K
Revenue grew as 2026 EBITDA guidance increased

Evolent Health reported September 30, 2026 quarter revenue of 725,367 thousand dollars and adjusted EBITDA of 34,257 thousand dollars. It raised 2026 adjusted EBITDA guidance to $130.0 million to $135.0 million and reiterated $2.6 billion to $2.7 billion revenue guidance.

Financial results
4 source passages
Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2026. Revenue | 725,367 Adjusted EBITDA | 34,257 Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6 billion to $2.7 billion and raising its Adjusted EBITDA range to $130.0 million to $135.0 million. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 51.3% despite wider operating loss

Evolent Health reported revenue of $725.4 million for the three months ended September 30, 2026, up 51.3%, compared to 2025. Nine-month revenue rose 33.2% to $1.9 billion, while operating losses widened in both periods.

Revenue $725.37M ▲ 51.3% Net loss $23.57M Diluted EPS -$0.21
Read from the MD&A section
4 source passages
Total revenue increased by $245.8 million, or 51.3%, to $725.4 million for the three months ended September 30, 2026, as compared to 2025. Total revenue increased $466.6 million, or 33.2%, to $1.9 billion for the nine months ended September 30, 2026, compared to the same period in 2025. Operating income (loss) | (6,188) | 886 | (7,074) | (798.4)% | (26,348) | (1,907) | (24,441) | (1,281.6) % The following table represents Evolent’s revenue disaggregated by line of business (in thousands): Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $652.52M ▲ 46.9% Net loss $28.36M Diluted EPS -$0.25
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.34B
Trailing 12 months
Net income (TTM)
−$507.69M
Trailing 12 months
Revenue growth YoY
+51.3%
Year over year
Operating margin
-18.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$818.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
+5.7%
Trailing year
Short interest
9.4%
Latest settlement · 7.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Q3 delivered sequential revenue and adjusted EBITDA growth, better MER, raised full-year adjusted EBITDA guidance, customer expansions, AI-driven efficiency, and a 2027 outlook of at least $150 million at the adjusted EBITDA guidance midpoint. Risks include year-over-year margin deterioration, lower specialty revenue, a smaller Q4 MER benefit, $776 million of net debt, constrained cash flow, and 2027 attrition, scope-adjustment, and investment headwinds.

Bullish
  • + Management retained confidence that the midpoint of 2027 adjusted EBITDA guidance will be $150 million or higher.
  • + Evolent plans to deploy up to $50 million toward reducing debt by year-end while preserving financial flexibility.
Bearish
  • − Specialty technology and services revenue declined approximately 7% sequentially to $73 million.
  • − Management expects a smaller sequential MER improvement in Q4 because part of the anticipated benefit was realized in Q3.
  • − Membership attrition, contract scope adjustments, and targeted investments are expected to offset 2027 earnings tailwinds.
  • − Full-year operating cash flow remains constrained by annual cash interest and the timing of reconciliation payments.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −1%
below
Price vs 50-day avg −7%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 43%
mid-range
Momentum
relative strength
Weak
1-month return −19%
trailing
6-month return −2%
trailing
YTD return −3%
this year
Relative strength +8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.38% of shares out · ▼ -10.9% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
195 holders — near 3-yr low, contrarian setup
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth −2%
Y/Y
EPS growth −526%
Y/Y
Free cash flow $3.3M
Balance sheet $818.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −50%
past year
ATR 10.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the Earnings Call filed Nov 5, 2026
full-year 2026
Full-year revenue guidance Maintained $2.6B – $2.7B
Aug 6, 2026 $2.6B – $2.7B changed to Nov 5, 2026 $2.6B – $2.7B
prior FY $1.88B midpoint +41.2% Y/Y
Adjusted EBITDA guidance Non-GAAP Raised $130M – $135M
Aug 6, 2026 $120M – $135M changed to Nov 5, 2026 $130M – $135M
Medical expense ratio (MER) Maintained 93%
Aug 6, 2026 93% changed to Nov 5, 2026 93%
fourth quarter 2026, sequential increase
Sequential increase in adjusted EBITDA Non-GAAP $11M – $16M
for the year 2026
Adjusted cost of revenue, excluding medical claims, but includin Non-GAAP Maintained $675M
May 7, 2026 $675M changed to Nov 5, 2026 $675M
Capital expenditures $26M – $28M
full year 2026
Cash flow from operations Maintained $10M – $20M
Aug 6, 2026 $10M – $20M changed to Nov 5, 2026 $10M – $20M
by the end of the year 2026
Debt reduction (deploy towards reducing outstanding indebtedness up to $50M
2027
Midpoint of adjusted EBITDA guidance Non-GAAP at least $150M
full-year
MER Maintained 93%
Aug 6, 2026 93% changed to Nov 5, 2026 93%
by the end of the year
Deploy towards reducing outstanding indebtedness up to $50M
27
EBITDA $150M
Previous outlook earlier release · from the Earnings Call filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted cost of revenue, excluding medical claims, plus adjuste · full-year 2026 $675M
Software development and capital expenditures · for 2026 $25M – $30M
Revenue growth · 2027 at least 25%
Adjusted EBITDA midpoint · 2027 at least $150M
Revenue growth · in 2027 at least 25%
Adjusted EBITDA · 2027 midpoint of adjusted EBITDA outlook at least $150M
Adjusted cost of revenue, excluding medical claims but including · full-year 2026 $675M
Cash flow from operations · for the year $10M – $20M
Prior guidance period ended · from the Earnings Call filed Feb 24, 2026
Adjusted EBITDA · the first quarter $20M
Sequential improvement · Q3 $10M – $15M
Guided vs delivered · last 5 settled
Revenue full year
guided $1.87B – $1.88B
$1.88B In line
Revenue Q4 2025
guided $462M – $472M
$468.72M In line
Total revenue full year
guided $845M – $880M
$907.96M Beat +5.3%
Total revenue second quarter
guided $210M – $225M
$222.06M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−1% Neutral
Price vs 50-day avg
−7% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
43% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.38% of shares out · ▼ -10.9% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
195 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2 Now $4 · 43% Range high $6
vs 200-day avg -1% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA margin non-GAAP 4.5% nine months ended September 30, 2026 —
Adjusted income attributable to common shareholders non-GAAP 7.27M nine months ended September 30, 2026 —
Adjusted income per share attributable to common shareholders non-GAAP $0.06 nine months ended September 30, 2026 —
Medical Expense Ratio excluding Evolent Care Partners non-GAAP 95.3% Q2 2026 —
Performance Suite revenue excluding revenue from Evolent Care Partners non-GAAP $484.5M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EVH
Evolent Health, Inc.
this stock
$441.11M -2.5% -1.8% — 9.4%
VEEV
Veeva Systems Inc
$43.10B +19.3% +28.1% 43.6 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.50B +67.8% +28.2% 34.2 5.8%
TEM
Tempus AI, Inc.
$9.86B -8.5% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
195
% held
92.6%
Net QoQ
-7.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
169
View
Short & Settlement
Short Interest Falling
Shares short
10.6M
Days to cover
7.0d
Change
-1.3M sh
View
Short Volume
Short vol %
68%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
114.2K
Value
$387.3K
As of
Oct 2, 2026
View
Off-Exchange
Off-exchange %
32.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Greg Gianforte
Amount
$50.0K–$100.0K
Traded
May 11, 2020
View
Financials
Financials
Revenue (FY)
$1.9B
Net income (FY)
$-534.5M
EPS diluted
$-5.07
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
12

Evolent Health reported revenue of $725.4 million for the three months ended September 30, 2026, up 51.3%, compared to 2025. Nine-month revenue rose 33.2% to $1.9 billion, while operating losses widened in both periods.

View
Proposed Sales
Value
$93.9K
Shares
9.2K
Filed
Feb 25, 2025
View
Exempt Offerings
Offering
$728.0K
Filed
May 26, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Evolent Announces Third Quarter 2…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
EVH -20.4% -18.8% -1.5% -9.3% -2.5%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -11.9% -9.5% +7.7% -0.6% -3.7%
Key facts CIK 1628908 CUSIP 30050B101 13F (30d) 212 filings 189 filers Visit website Investor relations